Necitumumab
- TRADE NAME: Portrazza (Lilly)
- INDICATIONS: Metastatic squamous non-small cell lung cancer (in combination with cisplatin and gemcitabine)
- CLASS: Epidermal growth factor receptor (EGFR) inhibitor / antagonist, Monoclonal antibody
- HALF-LIFE: 14 days
FDA APPROVAL DATE: 11/27/2015
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:None known
PREGNANCY CATEGORY: N/A
Can cause fetal harm
See separate entries for cisplatin and gemcitabine.
CARDIOPULMONARY ARREST and HYPOMAGNESEMIA
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric